Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus. Rheumatology (Oxford) 2023 Dec 01;62(12):3804-3810

Date

08/18/2023

Pubmed ID

37594751

DOI

10.1093/rheumatology/kead416

Scopus ID

2-s2.0-85178359347 (requires institutional sign-in at Scopus site)   3 Citations

Abstract

Interleukin-6 (IL-6) is one of the cytokines implicated in murine and human SLE. Only a few small studies have investigated IL-6 inhibition in human SLE. Currently, there are no studies registered in clinicaltrials.gov to assess the IL-6 targeted therapy in SLE, yet its role in the future remains to be defined. This narrative review analyses these and potential areas of future studies with IL-6 targeted therapy in SLE.

Author List

Nepal D, Gazeley D

Author

David J. Gazeley MD Associate Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Animals
Cytokines
Humans
Interleukin-6
Lupus Erythematosus, Systemic
Mice
Severity of Illness Index